Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2022

Updated Results of Dalpiciclib Plus Fulvestrant Therapy in Patients With HR+/HER2− Advanced Breast Cancer

Annals of Oncology


Additional Info

Annals of Oncology
229P Dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
Ann. Oncol 2022 Sep 01;33(suppl 7)S642-S643, P Zhang, QY Zhang, X Hu, et al

Further Reading